Goff Corinne Le
Known title: President and CEOCIK: 0001840912
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Transaction History
| VTRS | ▲ Buy | Option Exercise | 39,344 | $0 | 4/15/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,617 | $22K | 4/15/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 17,450 | $242K | 4/15/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 3,644 | $0 | 4/15/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 44,165 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 19,588 | $277K | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 2,193 | $0 | 3/6/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 973 | $14K | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 36,720 | $0 | 3/4/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 16,300 | $240K | 3/4/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 3,053 | $0 | 3/4/2026 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 1,355 | $20K | 3/4/2026 | View on chart |
| VTRS | ▼ Sell | Open Market | 7,032 | $72K | 9/11/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,768 | $0 | 4/15/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 855 | $6K | 4/15/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 39,344 | $0 | 4/15/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 19,023 | $142K | 4/15/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 36,721 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 521 | $5K | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,173 | $0 | 3/4/2025 | View on chart |
| VTRS | ▼ Sell | Tax Withholding | 16,276 | $153K | 3/4/2025 | View on chart |
| IMNN | ▲ Buy | Grant | 53,000 | $0 | 7/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal
Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.